Dystonia, focal, task-specific

Summary

Dystonia, focal, task-specific (MONDO:0044871) is a disease and 9 clinical trials. Top therapeutic interventions include botulinum toxin type a. A subtype of focal dystonia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	dystonia, focal, task-specific
Mondo ID	MONDO:0044871
MeSH	C566973
OMIM	611284
SNOMED CT	230330004
UMLS	C1969807
MedGen	370752
GARD	0006458
Is cancer (heuristic)	no

Also known as: dystonia, focal, task-specific · focal hand dystonia · focal task-specific dystonia · FTSD · musician’s cramp · musician’s dystonia · occupational cramp · occupational dystonia · task-specific dystonia · task-specific focal dystonia

Disease family

This is a subtype of focal dystonia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › movement disorder › extrapyramidal and movement disease › dystonic disorder › focal dystonia › dystonia, focal, task-specific

Related subtypes (11): anismus, cervical dystonia, focal hand dystonia, oculogyric crisis, spasmodic dystonia, craniofacial dystonia, X-linked dystonia-parkinsonism, torsion dystonia 7, benign essential blepharospasm, dystonia 23, oromandibular dystonia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5
PHASE3	1
PHASE2	1
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03977493	PHASE3	RECRUITING	IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia
NCT02911103	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Deep Brain Stimulation Surgery for Focal Hand Dystonia
NCT00106782	PHASE2	COMPLETED	Transcranial Electrical Polarization to Treat Focal Hand Dystonia
NCT01884064	PHASE1	COMPLETED	Repetitive Transcranial Magnetic Stimulation for the Treatment of Focal Hand Dystonia
NCT06367608	Not specified	RECRUITING	MRgFUS Pallidotomy for the Treatment of Task Specific Focal Hand Dystonia (TSFD)
NCT00325091	Not specified	COMPLETED	Long-Term Motor Learning in Focal Hand Dystonia
NCT00376753	Not specified	COMPLETED	Muscle Contraction in Patients With Focal Hand Dystonia
NCT00579033	Not specified	UNKNOWN	Somatosensory Processing in Focal Hand Dystonia
NCT03664375	Not specified	COMPLETED	Impact Of Physiotherapy And Botox In Improving Functional Outcomes Among Post Stroke Focal Dystonia Patients

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BOTULINUM TOXIN TYPE A	4	1